SCHEMBL29019406

SCHEMBL29019406

Oc1ccc(Cl)c(F)c1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C2 P52895 1/20 0.45
▸ AKR1C1 Q04828 1/20 0.45
▸ AURKA O14965 1/20 0.38
▸ TPX2 Q9ULW0 1/20 0.38
▸ MAPT P10636 3/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ SCN5A Q14524 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ THRA P10827 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ ACLY P53396 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ TRPV1 Q8NER1 2/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046979 0.76 AKR1C2 (0.44) AKR1C2AKR1C1AURKATPX2MAPT
SCHEMBL28056213 0.71 AKR1C2 (0.45) AKR1C2AKR1C1AURKATPX2MAPT
SCHEMBL966803 0.71 AKR1C2 (0.45) AKR1C2AKR1C1AURKATPX2MAPT
SCHEMBL30366911 0.69 KIF11 (0.40) AURKATPX2MAPTSCN5ATRPV1
SCHEMBL28716842 0.68 MAOB (0.41) AURKATPX2MAPTSCN5AMAPK1
SCHEMBL508237 0.68 AURKA (0.57) AKR1C2AKR1C1AURKATPX2MAPT
SCHEMBL23041015 0.67 KIF11 (0.41) AKR1C2AKR1C1AURKATPX2SCN5A
SCHEMBL30046652 0.67 KIF11 (0.41) SCN5AL3MBTL1
SCHEMBL8470711 0.67 MEN1 (0.49) AURKATPX2MAPTFFAR1FFAR4
SCHEMBL22816653 0.67 ESR1 (0.56) AKR1C2AKR1C1AURKATPX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110003123-B Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders 艾尼纳制药公司 2023-06-23 — — CN disclosed
Send feedback